Table 1 Clinical and molecular characteristics of the patients with IMA
From: Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung
Characteristics | All (n = 79) |
|---|---|
Age, median [interquartile range] | 62.0 [54.0–72.0] |
Female, n (%) | 42 (53.2) |
ECOG PS, n (%) (n = 61) | |
 0 | 2 (3.3) |
 1 | 59 (96.7) |
Smoking history, n (%) | |
 Never | 41 (51.9) |
 Former | 36 (45.6) |
 Current | 2 (2.5) |
Initial Chest CT findings, n (%) | |
 Solid mass | 39 (49.4) |
 Consolidation | 40 (50.6) |
Initial Clinical Stage, n (%) | |
 I | 3 (3.8) |
 II | 11 (13.9) |
 III | 14 (17.7) |
 IV | 51 (64.6) |
M stage, n (%) (n = 77) | |
 M1a | 58 (75.3) |
 M1b | 8 (10.4) |
 M1c | 11 (14.3) |
Mutational status, n (%) | |
 EGFR mutation (n = 79) | 8 (10.1) |
 ALK rearrangement (n = 69) | 4 (5.8) |
 ROS1 rearrangement (n = 2) | 0 (0.0) |
 KRAS mutation (n = 12) | 11 (91.7) |
PD-1 expression (n = 33) | 14 (42.4) |